CTLA4 and autosomal dominant polycystic kidney disease: However, inhibiting two immunological checkpoints with anti-PD-1 and anti-CTLA-4 improved PKD outcomes in adult-onset ADPKD mice, while neither monotherapy reduced PKD severity.55